Blue Owl Capital Holdings LP lessened its stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 7.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,769,199 shares of the company's stock after selling 235,000 shares during the period. Pliant Therapeutics accounts for approximately 8.6% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 3rd largest holding. Blue Owl Capital Holdings LP owned about 4.55% of Pliant Therapeutics worth $36,470,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in PLRX. Silverarc Capital Management LLC purchased a new position in Pliant Therapeutics in the fourth quarter valued at about $17,326,000. Adage Capital Partners GP L.L.C. purchased a new position in Pliant Therapeutics in the fourth quarter valued at about $8,556,000. JPMorgan Chase & Co. grew its stake in Pliant Therapeutics by 300.8% in the fourth quarter. JPMorgan Chase & Co. now owns 197,251 shares of the company's stock valued at $2,598,000 after purchasing an additional 148,039 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Pliant Therapeutics by 20.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 547,297 shares of the company's stock valued at $7,206,000 after purchasing an additional 91,131 shares during the last quarter. Finally, Candriam S.C.A. grew its stake in Pliant Therapeutics by 8.0% in the fourth quarter. Candriam S.C.A. now owns 900,104 shares of the company's stock valued at $11,854,000 after purchasing an additional 66,888 shares during the last quarter. Hedge funds and other institutional investors own 97.30% of the company's stock.
Pliant Therapeutics Stock Performance
Shares of NASDAQ:PLRX traded up $0.03 during midday trading on Tuesday, reaching $1.50. The company's stock had a trading volume of 228,784 shares, compared to its average volume of 1,060,811. The firm has a market capitalization of $91.77 million, a PE ratio of -0.45 and a beta of 1.46. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The stock has a fifty day moving average of $1.70 and a 200 day moving average of $8.62. Pliant Therapeutics, Inc. has a twelve month low of $1.10 and a twelve month high of $16.52.
Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.17. On average, equities analysts expect that Pliant Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on PLRX shares. Oppenheimer reiterated a "market perform" rating on shares of Pliant Therapeutics in a research note on Monday, February 10th. Wells Fargo & Company lowered their price target on Pliant Therapeutics from $4.00 to $3.00 and set an "equal weight" rating for the company in a report on Tuesday, March 4th. Royal Bank of Canada lowered their price target on Pliant Therapeutics from $4.00 to $3.00 and set a "sector perform" rating for the company in a report on Tuesday, March 4th. Cantor Fitzgerald reissued a "neutral" rating on shares of Pliant Therapeutics in a report on Tuesday, March 4th. Finally, Canaccord Genuity Group reissued a "hold" rating and issued a $4.00 price target (down previously from $43.00) on shares of Pliant Therapeutics in a report on Monday, February 10th. Twelve investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Pliant Therapeutics currently has an average rating of "Hold" and a consensus target price of $13.31.
Read Our Latest Research Report on PLRX
Pliant Therapeutics Profile
(
Free Report)
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
See Also
Before you consider Pliant Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.
While Pliant Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
